Omecamtiv Mecarbil in Patients with Severe Heart Failure: An Analysis from Global Approach to Lowering Adverse Cardiac Outcomes through Improving Contractility in Heart Failure (GALACTIC-HF)

29 June 2021 (00:00 - 00:00)

Organised by:

Sign in for access options

Sign in for access options

About the speaker

Professor G Michael Felker

Duke University Medical Center, Durham (United States of America)

13 More presentations in this session

Presentation thumbnail

Association of Baseline Cardiac Biomarkers on Clinical Outcomes and Vericiguat Treatment Effect in Heart Failure with Reduced Ejection Fraction: Insights from the VICTORIA Trial

Associate Professor C. DeFilippi (Baltimore, US)

Presentation thumbnail

Efficacy and Safety of Antithrombotic Strategies in Patients With Atrial Fibrillation and Recent ACS or PCI With and Without A History of Heart Failure: Insights From the AUGUSTUS Trial

Doctor M. Fudim (Durham, US)

Presentation thumbnail

Nurse Intervention for Less Chronic Heart Failure Study

Professor S. Stewart (Fremantle, AU)

Presentation thumbnail

Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide level: Insights from the GALACTIC-HF trial.

Professor J. McMurray (Glasgow, GB)

Presentation thumbnail

Telemedical Interventional Management in Heart Failure

Professor F. Koehler (Berlin, DE)

Access the full session

Session thumbnail

Clinical Trial Updates

The Event

Heart Failure 2021

29 June - 1 July 2021

You may be interested in

Congress Presentation

Breaking the barriers in guideline-directed medical therapy implementation in heart failure - discussion

Congress Presentation

The role of ICD therapy in heart failure in 2024. What is the holistic approach to treat heart failure?

Congress Session

Guideline-directed medical therapy implementation in special clinical scenarios

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources